Takeda Pharmaceutical (TAK) Cash from Restructuring (2019)
Takeda Pharmaceutical (TAK) recorded quarterly Cash from Restructuring of $90.1 million in Q1 2019.
Takeda Pharmaceutical (TAK) Cash from Restructuring (2019) Analysis & Trends
Takeda Pharmaceutical's Cash from Restructuring history runs 1 years deep, the most recent figure standing at $90.1 million for Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Takeda Pharmaceutical | 169,609.19 | -6.60 Bn | 4.39 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 90.07 Mn |